First Investigator Meeting for Cellestia’s CB-103-C-101 first-in-human study with CB-103 (Barcelona, September 19th 2017).
First Investigator Meeting for Cellestia’s CB-103-C-101 first-in-human study with CB-103 (Barcelona, September 19th 2017).
Management Team and Scientific Advisory Board extension
Cellestia Enters Clinical Development for its Lead Compound CB-103
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.